诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

交易中 11-19 11:32:52

6.330

-0.080

-1.25%

最高6.540	最低6.220	成交量430.90万
今开6.420	昨收6.410	日振幅4.99%
总市值111.57亿	流通市值94.70亿	总股本17.63亿
成交额2,729万	换手率0.29%	流通股本14.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":6.33,"timestamp":1731987067509,"preClose":6.41,"halted":0,"volume":4309000,"delay":0,"floatShares":1496000000,"shares":1762567202,"eps":-0.39809322,"marketStatus":"交易中","marketStatusCode":2,"change":-0.08,"latestTime":"11-19 11:32:52","open":6.42,"high":6.54,"low":6.22,"amount":27293340,"amplitude":0.049922,"askPrice":6.33,"askSize":34000,"bidPrice":6.32,"bidSize":74000,"shortable":3,"etf":0,"ttmEps":-0.23598857961619868,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1731988800000},"adr":0,"listingDate":1584892800000,"adjPreClose":6.41,"openAndCloseTimeList":[[1731979800000,1731988800000],[1731992400000,1732003200000]],"volumeRatio":1.551855,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":12.4,"timestamp":1731986996000,"preClose":11.85,"halted":0,"volume":4448895,"delay":0,"premium":"-52.55"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2484649772","title":"BTK赛道蓝海变红海，诺诚健华何时能盈利？","url":"https://stock-news.laohu8.com/highlight/detail?id=2484649772","media":"投资时间","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484649772?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:48","pubTimestamp":1731919725,"startTime":"0","endTime":"0","summary":"今年前三季度，诺诚健华实现营业收入6.98亿元，同比增长29.85%；归母净亏损2.75亿元，同比收窄48.15%标点财经、投资时间网研究员&nbsp; 习羽业绩承压之下，这家创新药龙头企业商业化的步伐正在加快。11月15日，诺诚健华宣布，公司自主研发的新型TYK2抑制剂ICP-332治疗特应性皮炎（AD）的III期注册临床试验在中国完成首例受...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OEff2Oj4wJ7U-bKDELbFUzsabOD8CkQskJFWhzZdVrG-8AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OEff2Oj4wJ7U-bKDELbFUzsabOD8CkQskJFWhzZdVrG-8AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241118A06LZP00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241118A06LZP00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2484648783","title":"BTK赛道蓝海变红海，诺诚健华何时能盈利？","url":"https://stock-news.laohu8.com/highlight/detail?id=2484648783","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484648783?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:46","pubTimestamp":1731919570,"startTime":"0","endTime":"0","summary":"2024年前三季度，诺诚健华营收同比增长29.85%，对此公司表示，收入增长主要归功于期内奥布替尼销售收入同比增长45.0%。而第三季度其销售收入则同比增长75.5%，不过，在奥布替尼取得今日地位的背后，诺诚健华也付出了高昂的代价。2022年—2023年，诺诚健华的研发费用分别为6.49亿元及7.57亿元，均高于公司同期收入水平。因此，诺诚健华欲实现扭亏为盈也要正视这一问题。公开资料显示，自身免疫性疾病成为诺诚健华现阶段重点拓展领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118164920abcbfc14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118164920abcbfc14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688428","09969"],"gpt_icon":0},{"id":"2484610857","title":"11月18日诺诚健华-U跌6.77%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484610857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484610857?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:13","pubTimestamp":1731917603,"startTime":"0","endTime":"0","summary":"证券之星消息，11月18日诺诚健华-U跌6.77%，收盘报11.85元，换手率3.13%，成交量8.34万手，成交额1.01亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共17家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为25.32亿元，最新净值1.0508，较上一交易日下跌1.96%，近一年下跌9.1%。鹏华医药科技股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800019726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688428","09969","09939","BK1515","BK0239","BK1161","BK1574"],"gpt_icon":0},{"id":"2484693403","title":"财通证券：诺诚健华肿瘤自免两开花，公司进入快速增长期","url":"https://stock-news.laohu8.com/highlight/detail?id=2484693403","media":"财中社","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484693403?lang=zh_cn&edition=full","pubTime":"2024-11-18 11:10","pubTimestamp":1731899400,"startTime":"0","endTime":"0","summary":"财中社11月18日电财通证券发布研报称，诺诚健华 以奥布替尼为基石，积极布局血液瘤和自免领域：奥布替尼于2020年12月在国内附条件获批上市，截至目前，奥布替尼已获批3项血液瘤适应症，目前在研3项血液瘤适应症进度靠前且无获批同类产品。在研4项自免适应症也不断有临床数据读出，MS和ITP均已进入Ⅲ期临床。目前13款药物在研，2款已商业化品种及30多项临床试验。首次覆盖，给予“增持”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118111348abcaf04c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118111348abcaf04c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601108","09969","688428","BK0276","BK0239"],"gpt_icon":0},{"id":"2484866269","title":"诺诚健华(09969)下跌5.11%，报6.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484866269","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484866269?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:59","pubTimestamp":1731895168,"startTime":"0","endTime":"0","summary":"11月18日，诺诚健华(09969)盘中下跌5.11%，截至09:59，报6.5元/股，成交1029.41万元。诺诚健华医药有限公司是一家主要从事为恶性肿瘤和自身免疫性疾病患者研发创新药的生物医药高科技公司。公司构建了从源头创新到商业化的全产业链平台，并在全球多个主要城市设有分支机构，致力于提供创新疗法。截至2024年三季报，诺诚健华营业总收入6.98亿元、净利润-2.75亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18095945387055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688428","BK1161","BK0239","BK1574","09969"],"gpt_icon":0},{"id":"2483004321","title":"亮眼业绩未能带飞股价，诺诚健华(09969)核心产品真实价值几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2483004321","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483004321?lang=zh_cn&edition=full","pubTime":"2024-11-15 19:44","pubTimestamp":1731671043,"startTime":"0","endTime":"0","summary":"积极的三季度财报数据，却未能带动诺诚健华股价“闻声上涨”。公开信息显示，截至2024年上半年，诺诚健华拥有13款在研产品，并有2款产品进入商业化阶段。与竞争对手相比，奥布替尼的获批时间明显较晚，且目前尚未获得FDA批准，落后于同为二代产品的阿卡替尼和泽布替尼。根据原先的协议约定，渤健将向诺诚健华一次性支付不可退还和不予抵扣的首付款1.25亿美元，最高还将有8.125亿美元的销售里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","09969","BK1574","BK1161","688428"],"gpt_icon":0},{"id":"2483844557","title":"诺诚健华11月14日主力资金流入10万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483844557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483844557?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:15","pubTimestamp":1731572135,"startTime":"0","endTime":"0","summary":"11月14日, 诺诚健华股价跌2.13%，报收6.89元，成交金额3299万元，换手率0.32%，振幅3.98%，量比0.62。诺诚健华今日主力资金净流入10万元，连续5日净流入，上一交易日主力净流入156万元，今日环比减少93.59%。该股近5个交易日上涨1.76%，主力资金累计净流入1039万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2230万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161551abc04e58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161551abc04e58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2483035330","title":"业绩向上，股价向下！生物科技股蕴藏投资机会？","url":"https://stock-news.laohu8.com/highlight/detail?id=2483035330","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483035330?lang=zh_cn&edition=full","pubTime":"2024-11-13 19:28","pubTimestamp":1731497301,"startTime":"0","endTime":"0","summary":"美东时间11月12日，再鼎医药（ZLAB.US）大跌6.85%，百济神州（BGNE.US）则下跌5.56%。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202411_1/91399957-d986-4ce3-a87a-53e008f85886.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202411_1/91399957-d986-4ce3-a87a-53e008f85886.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67348d5553243c06d087f4a7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["LU0307460666.USD","09688","IE00BPRC5H50.USD","BGNE","LU0417516571.SGD","BK4588","BK1161","09926","06160","LU1969619763.USD","LU0588546209.SGD","BK4526","LU0348783233.USD","BK4505","BK4548","BK4504","LU1794554557.SGD","LU2328871848.SGD","BK1583","BK1574","BK1588","BK1500","IE00B543WZ88.USD","BK4535","IE00B5MMRT66.SGD","LU1720050803.USD","BK4585","LU2488822045.USD","09969","BK4139","LU0348784397.USD"],"gpt_icon":0},{"id":"2483021413","title":"11月13日诺诚健华-U跌6.78%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483021413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483021413?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:06","pubTimestamp":1731485176,"startTime":"0","endTime":"0","summary":"证券之星消息，11月13日诺诚健华-U跌6.78%，收盘报13.34元，换手率4.06%，成交量10.8万手，成交额1.46亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共17家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为25.32亿元，最新净值1.122，较上一交易日下跌0.04%，近一年下跌2.6%。鹏华医药科技股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300025295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","BK0239","BK1161","159938","BK1574","09969","688428"],"gpt_icon":0},{"id":"2483654029","title":"仅靠奥布替尼放量、同类竞争加剧，诺诚健华前三季度继续亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2483654029","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483654029?lang=zh_cn&edition=full","pubTime":"2024-11-13 15:13","pubTimestamp":1731481980,"startTime":"0","endTime":"0","summary":"11月11日晚间，诺诚健华发布2024年第三季度报告，今年前三季度，诺诚健华实现营收6.98亿元，同比增长29.8%；归属于上市公司股东的净利润为-2.75亿元；净亏损为2.85亿元，同比收窄47.1%；毛利率86%，同比增长4.8%。亏损幅度进一步收窄，离不开诺诚健华核心产品奥布替尼销售放量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411133238410241.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411133238410241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2483302534","title":"仅靠奥布替尼放量、同类竞争加剧，诺诚健华前三季度继续亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2483302534","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483302534?lang=zh_cn&edition=full","pubTime":"2024-11-13 15:13","pubTimestamp":1731481980,"startTime":"0","endTime":"0","summary":"亏损幅度进一步收窄，离不开诺诚健华核心产品奥布替尼销售放量。今年第三季度奥布替尼实现销售收入2.76亿元，同比增长75.5%，创该产品上市以来单季最高收入。奥布替尼独撑业绩诺诚健华目前有两款产品上市，分别为奥布替尼和坦昔妥单抗。BTK抑制剂奥布替尼是诺诚健华首个实现商业化的产品，于2020年12月获批上市。BTK抑制剂竞争者不断涌入尽管奥布替尼在上市后快速放量，但BTK抑制剂竞争日趋激烈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113151407abbc645b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113151407abbc645b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09969","688428"],"gpt_icon":0},{"id":"2483904904","title":"港股异动 | 诺诚健华(09969)回落逾7% 前三季度亏损收窄至2.75亿 机构称三季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2483904904","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483904904?lang=zh_cn&edition=full","pubTime":"2024-11-13 13:59","pubTimestamp":1731477562,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华回落逾7%，截至发稿，跌6.14%，报7.03港元，成交额2549.6万港元。消息面上，诺诚健华此前公布截至今年9月底止首三季业绩，根据中国企业会计准则，营业额6.98亿元人民币，同比升29.8%；亏损收窄至2.75亿元，上年同期亏损5.31亿元。瑞银指出，诺诚健华第三季业绩超预期，亏损按年大幅缩小87.5%至1,360万元人民币，大幅优于市场预期的亏损约1.55亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1161","BK1574","688428","09969"],"gpt_icon":0},{"id":"2483872017","title":"浦银国际证券：给予诺诚健华中性评级，目标价位14.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483872017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483872017?lang=zh_cn&edition=full","pubTime":"2024-11-13 11:58","pubTimestamp":1731470339,"startTime":"0","endTime":"0","summary":"浦银国际证券有限公司胡泽宇,阳景近期对诺诚健华进行研究并发布了研究报告《奥布替尼销售略超预期，全年销售指引进一步上调至45%同比增速》，本报告对诺诚健华给出中性评级，认为其目标价位为14.50元，当前股价为13.11元，预期上涨幅度为10.6%。　　诺诚健华　　我们维持诺诚健华港股“买入”评级，上调港股目标价至9.2港元；上调A股目标价至人民币14.5元，但下调A股评级至“持有”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300017637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688428","09969"],"gpt_icon":0},{"id":"2483001435","title":"浦银国际证券给予诺诚健华持有评级，奥布替尼销售略超预期，全年销售指引进一步上调至45%同比增速","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001435","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483001435?lang=zh_cn&edition=full","pubTime":"2024-11-13 11:18","pubTimestamp":1731467915,"startTime":"0","endTime":"0","summary":"浦银国际证券11月13日发布研报称，给予诺诚健华（688428.SH，最新价：13.27元）持有评级，目标价格为14.5元。评级理由主要包括：1）两款TYK2抑制剂自免适应症如期推进；2）ICP-248有望于1H25迎来多项数据读出。风险提示：奥布替尼销售不及预期，主要药品出海不及预期，重要项目研发延误或者失败。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411133238270490.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411133238270490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969"],"gpt_icon":0},{"id":"2483018966","title":"诺诚健华盘中异动 大幅跳水5.07%报7.110港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483018966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483018966?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:10","pubTimestamp":1731463826,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时10分，诺诚健华股票出现异动，股价大幅下挫5.07%。诺诚健华股票所在的生物技术行业中，整体跌幅为1.87%。消息层面，截至10时10分，《瑞银：维持诺诚健华“买入”评级 目标价上调至9.8港元》资讯为影响诺诚健华的重要信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113101026abbb9a77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113101026abbb9a77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","09969","BK0239"],"gpt_icon":0},{"id":"2483018927","title":"诺诚健华(09969)下跌5.07%，报7.11元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483018927","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483018927?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:10","pubTimestamp":1731463826,"startTime":"0","endTime":"0","summary":"11月13日，诺诚健华(09969)盘中下跌5.07%，截至10:10，报7.11元/股，成交667.69万元。诺诚健华医药有限公司是一家主要从事为恶性肿瘤和自身免疫性疾病患者研发创新药的生物医药高科技公司。公司构建了从源头创新到商业化的全产业链平台，并在全球多个主要城市设有分支机构，致力于提供创新疗法。截至2024年三季报，诺诚健华营业总收入6.98亿元、净利润-2.75亿元。11月11日，2024财年三季报归属股东应占溢利-2.754亿人民币，同比增长48.15%，基本每股收益-0.16人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13101045231179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","09969","688428","BK1574","BK1161"],"gpt_icon":0},{"id":"2483109650","title":"诺诚健华减亏48%毛利率达85.95% 近七年累投超35亿研发大单品放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2483109650","media":"长江商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483109650?lang=zh_cn&edition=full","pubTime":"2024-11-13 08:33","pubTimestamp":1731457999,"startTime":"0","endTime":"0","summary":"近日，诺诚健华披露了2024年前三季度的财务报告，报告期公司实现营业收入6.98亿元，同比增长29.85%，归母净利润亏损2.75亿元，同比减亏48.15%。对于减亏的原因，诺诚健华解释称，随着奥布替尼销量增长，公司的销售费用使用效率提升及股权支付减少带来销售费用减少，归母净利润亏损大幅收窄。毛利率85.95%创三年新高目前，诺诚健华以大单品奥布替尼为核心，差异化布局了多款血液瘤产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113084105a231cfff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113084105a231cfff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574","688428"],"gpt_icon":0},{"id":"2483065221","title":"诺诚健华（688428）2024年三季报简析：营收上升亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2483065221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483065221?lang=zh_cn&edition=full","pubTime":"2024-11-13 06:02","pubTimestamp":1731448965,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诺诚健华发布2024年三季报。截至本报告期末，公司营业总收入6.98亿元，同比上升29.85%，归母净利润-2.75亿元，同比上升48.15%。本报告期诺诚健华盈利能力上升，毛利率同比增幅5.82%，净利率同比增幅59.25%。持有诺诚健华最多的基金为鹏华医药科技股票A，目前规模为25.32亿元，最新净值1.122，较上一交易日下跌0.04%，近一年下跌2.57%。公司目前正在进行PPMS国际三期临床，同时准备SPMS三期临床方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300004382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"gpt_icon":0},{"id":"2482706510","title":"诺诚健华：11月12日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2482706510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482706510?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:34","pubTimestamp":1731414885,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月12日诺诚健华发布公告称公司于2024年11月12日召开业绩说明会。公司目前正在进行PPMS国际三期临床，同时准备SPMS三期临床方案。公司2024年1-9月毛利率为86.0%,比上年同期的81.2%提高了4.8个百分点。公司后续奥布替尼销售收入及净利润数据敬请关注公司定期报告或不时发布的公告。诺诚健华主营业务：创新药的研发、生产及商业化。该股最近90天内共有7家机构给出评级，买入评级5家，增持评级2家；过去90天内机构目标均价为16.03。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200034790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","BK0239","BK1161","BK1574"],"gpt_icon":0},{"id":"1150754298","title":"异动解读 | 诺诚健华业绩亮眼 股价大涨5.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150754298","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150754298?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:35","pubTimestamp":1731400547,"startTime":"0","endTime":"0","summary":"2024年11月12日,创新生物医药企业诺诚健华盘中股价大涨5.89%,引发市场广泛关注。诺诚健华上日公布的2024年前三季度业绩显示,公司营业收入同比增长29.8%至6.98亿元人民币,亏损则较去年同期大幅收窄至2.75亿元人民币。数据显示,奥布替尼在第三季度实现销售2.76亿元,同比大涨75.5%;前三季度累计销售额达6.93亿元,增长45%。展望未来,除奥布替尼在自免疾病等适应症的推进外,诺诚健华新药渐露峥嵘。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09969"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.1419},{"period":"1month","weight":-0.0724},{"period":"3month","weight":0.4308},{"period":"6month","weight":0.2976},{"period":"1year","weight":-0.0869},{"period":"ytd","weight":-0.0697}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.120109},{"month":2,"riseRate":0.5,"avgChangeRate":0.019126},{"month":3,"riseRate":0,"avgChangeRate":-0.043789},{"month":4,"riseRate":0.6,"avgChangeRate":0.117148},{"month":5,"riseRate":0,"avgChangeRate":-0.072765},{"month":6,"riseRate":0.8,"avgChangeRate":0.122586},{"month":7,"riseRate":0.4,"avgChangeRate":-0.028005},{"month":8,"riseRate":0.2,"avgChangeRate":-0.086099},{"month":9,"riseRate":0.2,"avgChangeRate":-0.051427},{"month":10,"riseRate":0.4,"avgChangeRate":0.007797},{"month":11,"riseRate":0.8,"avgChangeRate":0.110276},{"month":12,"riseRate":0.75,"avgChangeRate":0.038159}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}